DUBLIN–(BUSINESS WIRE)–The “Ocular Inflammation Ongoing Global Clinical Trials Analysis and Outlook” report has been added to ResearchAndMarkets.com’s offering.Ocular Inflammation ongoing clinical trials report provides comprehensive analysis and tre…
Category: Business
Global Ocular Melanoma Ongoing Clinical Trials – Analysis & Outlook to 2022 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Ocular Melanoma Ongoing Global Clinical Trials Analysis and Outlook” report has been added to ResearchAndMarkets.com’s offering. Ocular Melanoma ongoing clinical trials report provides comprehensive analysis and trends in …
NovaBay Pharmaceuticals to Hold Second Quarter 2018 Conference Call on August 7, 2018
EMERYVILLE, Calif.–(BUSINESS WIRE)–NovaBay Pharmaceuticals to Hold Second Quarter 2018 Conference Call on August 7, 2018
Neuromyelitis Optica (Devic’s Syndrome) | A Drug Pipeline Analysis Report 2018 | Technavio
LONDON–(BUSINESS WIRE)–#Devicssyndrome–Technavio has published a new report on the drug development pipeline for neuromyelitis optica (Devic’s syndrome).
SeniorWell Expands Service to Ohio and Wisconsin
CHICAGO–(BUSINESS WIRE)–SeniorWell, a mobile healthcare company, today announced its expansion into Ohio and Wisconsin.
Ophthotech Corporation to Report Second Quarter 2018 Financial Results and Host Conference Call on Wednesday, August 1, 2018
NEW YORK–(BUSINESS WIRE)–Ophthotech announced that it will report its second quarter 2018 financial and operating results on Wed., Aug. 1, 2018.
Genentech Unveils Positive Phase II Results for the First-Ever Eye Implant to Achieve Sustained Delivery of a Biologic Medicine to Treat People With Wet Age-Related Macular Degeneration (AMD)
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced positive, top line results from the Phase II LADDER study evaluating the efficacy and safety of its investigational Port …
Data from BioTime’s OpRegen® Program to Be Presented at AAO 2018
ALAMEDA, Calif.–(BUSINESS WIRE)–BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that its abstract “PI/IIa Study of Subretinally Transplanted Human Embryonic Stem Cell-Derived RPE Cells in Advanced Dry-Form AMD Patients,” has been accepted for an oral presentation at the upcoming American Academy of Ophthalmology (AAO) meeting taking place from October 27th – October 30th, 2018, in Chicago, Illinois. “We are delighted
2018 Diabetic Retinopathy Pipeline Highlights – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Diabetic Retinopathy Pipeline Highlights – 2018” report has been added to ResearchAndMarkets.com’s offering. This report provides most up-to-date information on key pipeline products in the global Diabetic retinopathy mark…
Global Ocular Implants Market 2018-2022 | 13% CAGR Projection Over the Next Four Years | Technavio
LONDON–(BUSINESS WIRE)–#MedicalDevices–The global ocular implants market 2018-2022 is expected to post a CAGR of around 13% during the forecast period, according to Technavio.
Omeros Corporation Initiates Sales of OMIDRIA® in Europe
SEATTLE–(BUSINESS WIRE)–Omeros Corporation (NASDAQ: OMER) today announced initial sales of OMIDRIA® (phenylephrine and ketorolac intraocular solution) 1%/0.3% in Europe. OMIDRIA, approved and commercially available in the U.S., is also approved in the European Union (EU) for use in cataract and lens replacement surgery to maintain mydriasis (pupil dilation), prevent miosis (pupil constriction), and to reduce postoperative eye pain. These sales satisfy the “sunset clause” provision in the EU a
BioTime to Announce Second Quarter 2018 Results on August 2, 2018
ALAMEDA, Calif.–(BUSINESS WIRE)–BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that it will release second quarter 2018 financial and operating results on Thursday, August 2, 2018, after the close of the U.S. financial markets. The Company will host a conference call and webcast on Thursday, August 2, 2018, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss the results and recent corporate developments. The
Aura Biosciences Presents Interim Phase 1b/2 Data at the American Society of Retina Specialists (ASRS) Annual Meeting
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aura presented interim data from an open-label Phase 1b/2 study of light-activated AU-011 for the treatment of primary choroidal melanoma.
Uveal melanoma| A Pipeline Analysis Report 2018| Technavio
LONDON–(BUSINESS WIRE)–#InfectiousDiseases–Technavio has published a new report on the drug development pipeline for uveal melanoma, including a detailed study of the pipeline molecules.
Retinitis Pigmentosa | A Pipeline Analysis Report 2018 | Technavio
LONDON–(BUSINESS WIRE)–#RareDiseases–Technavio has published a new report on the drug development pipeline for retinitis pigmentosa, including a detailed study of the pipeline molecules.
Hemovent meldet „beeindruckende Ergebnisse“ aus GLP-konformer standardisierter In-vivo-Studie zur Langzeitanwendung des Systems für die extrakorporale Membranoxygenierung (ExtraCorporeal Membrane Oxygenation, ECMO) der nächsten Generation, Mobybox™
AACHEN, Deutschland–(BUSINESS WIRE)–Hemovent GmbH meldete heute den erfolgreichen Abschluss einer GLP-konformen standardisierten In-vivo-Studie zur Langzeitanwendung (7 Tage) ihrer neuartigen und tragbaren Bionique-Technologieplattform für die künstliche Lunge, die auf eine Vielzahl von Indikationen ausgerichtet ist: von der extrakorporalen Lebensunterstützung (ExtraCorporeal Life Support, ECLS) bis zur extrakorporalen CO2-Elimination (ExtraCorporeal CO2 Removal, ECCO2R). „Wir sind mit unsere
Researchers Move Closer to Completely Optical Artificial Neural Network
WASHINGTON–(BUSINESS WIRE)–#AI–Researchers have shown that it is possible to train artificial neural networks directly on an optical chip.
Glaukos Corporation to Release Second Quarter 2018 Financial Results after Market Close on August 2
SAN CLEMENTE, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, plans to release second quarter 2018 financial results after the market close on Thursday, August 2, 2018. The company’s management will discuss the results during a conference call and simultaneous webc
Global Night Vision Devices Market Analysis, Trends, Share, Size, Growth, Opportunity & Forecast 2018-2023 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Night Vision Devices Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2018-2023” report has been added to ResearchAndMarkets.com’s offering. The global Night Vision Devices market reached a val…
Secondo uno studio clinico, il LED SunLike di Seoul Semiconductor migliora la salute oculare e la qualità del sonno
ANSAN, Corea del Sud–(BUSINESS WIRE)–Seoul Semiconductor Co., Ltd. (KOSDAQ 046890), leader del settore in quanto a progettazione e produzione di diodi ad emissione di luce (light emitting diode, LED) operante su scala globale, ha annunciato che uno studio ha dimostrato che la sua tecnologia“SunLike” costituisce un LED ottimizzato per lo “human centric lighting” che è in grado di migliorare la salute oculare e la qualità del sonno. Il team del Laboratorio di informatica biomedica (Biomedical I